Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 12/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8382438 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL10758036 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL10757502 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL1795959 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL7843902 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL20969262 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL11179206 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL1793039 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL7756737 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A | |
| SCHEMBL5484071 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110133084-A | A kind of Integrated electrode detection card and preparation method thereof that can detect magnesium, chloride ion simultaneously | 南京晶捷生物科技有限公司 | 2019-08-16 | — | — | CN | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250332112-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4574172-A2 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-06-25 | — | — | EP | disclosed |
| EP-4466250-B1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4466250-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2024-11-27 | — | — | EP | disclosed |
| CN-118922401-A | Ionizable cationic lipids for lipid nanoparticles | 盖纳万科学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118317944-A | Acyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023144798-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2005030852-A2 | FLAME RETARDANT COMPOSITIONS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-04-07 | — | — | WO | disclosed |
| EP-1141140-B1 | NAPHTHALENEHYDRAZAMIMIDES AND PERYLENEHYDRAZAMIMIDES | CIBA SC HOLDING AG (CH) | 2002-09-04 | — | — | EP | disclosed |
| EP-1141140-A1 | NAPHTHALENEHYDRAZAMIMIDES AND PERYLENEHYDRAZAMIMIDES | Ciba SC Holding AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| US-6143890-A | Naphthalenehydrazamimides and perylenehydrazamimides | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000040657-A1 | NAPHTHALENEHYDRAZAMIMIDES AND PERYLENEHYDRAZAMIMIDES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-07-13 | — | — | WO | disclosed |
| US-5122186-A | Alylamine, hydoxylated polymerized oil, acidic resin dissolved in hydrophobic hydroxylic solvent | BASF CORPORATION (US) | 1992-06-16 | — | — | US | disclosed |
| US-4397965-A | HYDRAZINE DERIVATIVE BLOWING AGENT | UNIROYAL, INC. (US) | 1983-08-09 | — | — | US | disclosed |
| EP-0083173-A1 | Expandable and curable polyester composition and method for making same | UNIROYAL, INC. (US) | 1983-07-06 | — | — | EP | disclosed |
| US-4268486-A | REACTING WITH A HYDRAZINE COMPOUND AND SEPARATING TRIVALENT CHROMIUM COMPOUNDS | OLIN CORPORATION (US) | 1981-05-19 | — | — | US | disclosed |
| US-3962113-A | METHOD FOR ACCELERATING OXYGEN REMOVAL EMPLOYING AN AQUEOUS SOLUTION OF AN ALKYL HYDRAZINE | OLIN CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | DNM1 625/4885TSHR 1278/4885THRB 3756/4885 |
| US-20250332112-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | CETP, NPC1L1, ABCB4 | DNM1 847/4885TSHR 2640/4885THRB 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.